A Phase 1/2a, Open-label, Dose-escalation, Dose-expansion, Parallel AssignmentStudy to Evaluate the Safety and Clinical Activity of PBCAR0191 in Subjects withRelapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell AcuteLymphoblastic Leukemia (B-ALL)
Safety Study of PBCAR0191 in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma and r/r B-cell Acute Lymphoblastic Leukemia
Sponsor: Precision BioSciences, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAS9400
U.S. Govt. ID: NCT03666000
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this research study is to obtain information on the safety and effectiveness of PBCAR0191 to treat certain types of cancers. PBCAR0191 is a new investigational treatment for certain types of cancer of the blood, such as leukemia and lymphoma. It is made from a type of blood cells known as T cells. The T cells in PBCAR0191 came from people who have donated their blood. The donated T cells have been genetically changed, so that they may be able to kill some types of cancer cells.
Ran Reshef, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Have you been diagnosed with leukemia or lymphoma? Yes No
Have you received at least 2 prior chemotherapy treatment regimens? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator